ArticleCureus2025
A Study of Visual Outcomes and Spectral Domain Optical Coherence Tomography (SD-OCT) Biomarker Changes in Patients Treated With Ranibizumab for Diabetic Macular Edema in a Tertiary Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of Spectral Domain OCT Changes Following Anti-VEGF Therapy in Diabetic Macular Edema.Journal of pharmacy & bioallied sciences · 2026Article
- Phenotype-driven management of diabetic macular edema: multimodal imaging biomarkers and individualized therapy.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic macular edema (DME) is a leading cause of vision impairment in diabetes mellitus. Spectral-domain optical coherence tomography (SD-OCT) provides valuable biomarkers for assessing disease severity and treatment response. This study evaluates the visual outcomes and SD-OCT biomarker changes in patients treated with intravitreal ranibizumab at a tertiary hospital. MATERIALS AND
methodsA prospective cohort study was conducted on 50 Type 2 diabetes mellitus patients with center-involving DME at Employees' State Insurance Corporation (ESIC) Medical College and Hospital, Hyderabad, from July 2022 to December 2023. Inclusion criteria were best-corrected visual acuity (BCVA) <6/9 and central retinal thickness (CRT) ≥280 µm. Exclusion criteria included other retinal diseases, vision-impairing cataracts, or glaucoma. Patients received three monthly intravitreal ranibizumab injections and were followed up at one, two, three, and six months. BCVA, CRT, and SD-OCT biomarkers such as hyperreflective foci (HRF), subretinal neuroretinal detachment (SND), intraretinal cyst (IRC) size, disorganization of retinal inner layers (DRIL), ellipsoid zone (EZ) disruption, and external limiting membrane (ELM) disruption were assessed. Statistical analysis was performed using SPSS software, version 26 (IBM Corp., Armonk, NY).
resultsBCVA improved from 0.76±0.39 at baseline to 0.37±0.29 at six months (p<0.00001). CRT reduced from 473.66±111.65 µm to 326.64±71.37 µm (p<0.00001). HRF, SND, and IRC size showed significant regression. DRIL, EZ, and ELM disruption improved significantly (p<0.00001). There was no statistically significant association between OCT biomarker features and BCVA improvement of more than three lines.
conclusionIntravitreal ranibizumab significantly improves visual acuity and reduces retinal thickness in DME patients. SD-OCT biomarkers are valuable in monitoring treatment response and disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.